Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

PharmaNet’s Bioanalytical Laboratory Recognized by the Standards Council of Canada for Good Laboratory Practice Compliance

Published: Wednesday, June 29, 2011
Last Updated: Wednesday, June 29, 2011
Bookmark and Share
OECD GLP recognition consolidates Company’s position as the partner of choice for companies seeking assured international registration of their products.

PharmaNet Development Group, Inc., has announced that its bioanalytical laboratory in Quebec City, Canada, has received formal recognition from the Standards Council of Canada (SCC) for its compliance with the Organization for Economic Co-operation and Development (OECD) Principles of Good Laboratory Practice (GLP).

“After an in-depth review by a four-person inspection team, the Standards Council of Canada awarded us with official recognition of GLP compliance, acknowledging the premier level of quality and compliance maintained in our laboratory,” said Tony Jones, Executive Director, Quality Assurance and Compliance.

Mr. Jones continued, “We have a long track record of successful inspections from global regulatory bodies, including a re-certification from Brazil's ANVISA just prior to the SCC inspection. This OECD GLP recognition consolidates our position as the partner of choice for companies seeking assured international registration of their products.”

The final guidance describing the program was announced by Health Canada in April 2010. Thirty-four countries in North America, Europe and Asia constitute the OECD, an inter-governmental organization that pursues, among many other policies, the international harmonization of test methods and good laboratory practices.

Upholding the principles of GLP ensures that a laboratory’s quality system and management controls are consistent and reliable, which is essential for producing high quality and valid test data.

PharmaNet’s laboratories offer complete bioanalytical services for small and large molecules across the continuum of drug development.

The company’s other laboratory in Princeton, NJ, is also GLP-compliant. Together the labs offer an extensive method development and validation services, with more than 1000 validated assays and rapid sample handling capabilities.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Pharmanet Names Dr. George Scott Vice President of Bioanalytical Services
Dr. Scott will provide leadership for PharmaNet's GLP-compliant bioanalytical laboratories in the United States and Canada.
Friday, July 22, 2011
Valerie Palumbo Joins Pharmanet as Senior Vice President, Corporate Quality Assurance
Ms. Palumbo has more than twenty years of experience in the development and implementation of quality assurance programs in the FDA-regulated drug and medical device industries.
Tuesday, May 03, 2011
Pharmanet Appoint New Chief Medical Officer
PharmaNet Development Group, Inc. announces that Jeffrey Freitag, M.D., Senior Vice President, PharmaNet Consulting, will expand his role to become Chief Medical Officer of PharmaNet.
Monday, February 21, 2011
PharmaNet Launches New Brand Identity
PharmaNet Development Group, Inc. announced that it is launching a new brand identity and tagline, “PharmaNet Works For You”. The new brand and tagline reflect the Company’s promise to its clients to provide intelligent solutions to accelerate drug development programs consistent with the highest standards of regulatory compliance, quality and reliability.
Thursday, November 25, 2010
PharmaNet Development Group Collaborates with Abacus International
Collaboration is aimed to support patient registries and health economic programs in Europe.
Monday, July 26, 2010
Scientific News
Computational Model Finds New Protein-Protein Interactions
Researchers at University of Pittsburgh have discovered 500 new protein-protein interactions (PPIs) associated with genes linked to schizophrenia.
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Bioreactors Ready for the Big Time
Bioreactors are passive filtration systems that can reduce nitrate losses from farm fields.
Analysis of Dog Genome will Provide Insight into Human Disease
An important model in studying human disease, the non-coding RNA of the canine genome is an essential starting point for evolutionary and biomedical studies – according to a new study led by The Genome Analysis Centre (TGAC).
‘Mini-Brains’ to Study Zika
Novel tool expected to speed research on brain and drug development.
Finding Factors That Protect Against Flu
A clinical trial examining the body’s response to seasonal flu suggests new approaches for evaluating the effectiveness of seasonal flu vaccines.
New Insights into Gene Regulation
Researchers have solved the three-dimensional structure of a gene repression complex that is known to play a role in cancer.
Controlling RNA in Living Cells
Modular, programmable proteins can be used to track or manipulate gene expression.
Common Class of Cancer Drugs May Not Lead to Cognitive Decline
UCLA study refutes 2015 research suggesting anthracyclines could cause memory loss, other impairments.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!